Expanded biomarker results from a phase I dose escalation study of GDC-0032, a beta isoform-sparing PI3K inhibitor

被引：0

作者：

Wilson, Timothy R. ^{[1
]}

Savage, Heidi ^{[1
]}

O'Brien, Carol ^{[1
]}

Sanabria, Sandra ^{[1
]}

Lin, Ray S. ^{[1
]}

Wagle, Marie-Claire ^{[1
]}

Yan, Yibing ^{[1
]}

Lackner, Mark R. ^{[1
]}

Parmar, Hema ^{[1
]}

Hsu, Jerry Y. ^{[1
]}

Juric, Dejan ^{[2
]}

Krop, Ian E. ^{[3
]}

Ramanathan, Ramesh K. ^{[4
]}

Von Hoff, Daniel D. ^{[4
]}

Baselga, Jose ^{[5
]}

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

[2] Massachusetts Gen Hosp, Boston, MA 02114 USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Virginia G Piper Canc TGen, Scottsdale, AZ USA

[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

CANCER RESEARCH | 2014年 / 74卷 / 19期

关键词：

D O I：

10.1158/1538-7445.AM2014-915

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

915

引用

页数：2

共 50 条

[1] GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase la dose escalation study.
Juric, Dejan
Krop, Ian
Ramanathan, Ramesh K.
Xiao, Jim
Sanabria, Sandra
Wilson, Timothy R.
Choi, YounJeong
Parmar, Hema
Hsu, Jerry
Baselga, Jose
Von Hoff, Daniel D.
[J]. CANCER RESEARCH, 2013, 73 (08)
[2] PRECLINICAL EVALUATION OF THE B ISOFORM-SPARING PI3K INHIBITOR GDC-0032 AND PREDICTION OF ITS HUMAN PHARMACOKINETICS
Pang, Jodie
Baumgardner, Matthew
Cheong, Jonathan
Edgar, Kyle
Heffron, Timothy P.
Le, Hoa
Ndubaku, Chudi O.
Olivero, Alan G.
Plise, Emile G.
Staben, Steven T.
Wallin, Jeff
Wong, Susan
Zhang, Xiaolin
Salphati, Laurent
[J]. DRUG METABOLISM REVIEWS, 2014, 45 : 219 - 219
[3] Part I: Discovery of β-sparing PI3K inhibitor GDC-0032 by optimization of unbound drug exposure
Ndubaku, Chudi O.
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
[4] Part II: Development of a manufacturing route to PI3K β-sparing inhibitor GDC-0032 (Taselisib)
Remarchuk, Travis
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
[5] Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors.
Olivero, Alan G.
Heffron, Timothy P.
Baumgardner, Matthew
Belvin, Marcia
Ross, Leanne Berry
Blaquiere, Nicole
Bradley, Erin
Castanedo, Georgette
Derynck, Mika
Do, Steven
Dotson, Jennafer
Dudley, Danette
Edgar, Kyle
Folkes, Adrian
Francis, Ross
Gianetti, Tony
Goldsmith, Richard
Goldsmith, Paul
Guan, Jane
Harrison, Trevor
Heald, Robert
Hsu, Jerry
Jackson, Phillip
Jones, Graham
Kim, Amy
Kolesnikov, Aleks
Lackner, Mark
Lee, Leslie
Lesnick, John
Lewis, Cristina
Mamounas, Michael
McLean, Neville
Murray, Jeremy
Ndubaku, Chudi
Nonomiya, Jim
Pang, Jodie
Pegg, Neil
Prior, Wei Wei
Salphati, Laurent
Sampath, Deepack
Sideris, Stephen
Siu, Michael
Staben, Steven
Sutherlin, Daniel
Ultsch, Mark
Wallin, Jeff
Wang, Lan
Wiesmann, Christian
Zhang, Xiaolin
Friedman, Lori S.
[J]. CANCER RESEARCH, 2013, 73 (08)
[6] POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
Baird, Richard D.
van Rossum, Annelot G. J.
Oliveira, Mafalda
Beelen, Karin
Gao, Meiling
Schrier, Mariette
Mandjes, Ingrid A. M.
Garcia-Corbacho, Javier
Vallier, Anne-Laure
Dougall, Greig
van Werkhoven, Erik
Linossi, Constanza
Kumar, Sanjeev
van Tinteren, Harm
Callari, Maurizio
Beddowes, Emma
Perez-Garcia, Jose-Manuel
Rosing, Hilde
Platte, Else
Nederlof, Petra
Schot, Margaret
Schultink, Aurelia de Vries
Bernards, Rene
Saura, Cristina
Gallagher, William
Cortes, Javier
Caldas, Carlos
Linn, Sabine C.
[J]. CLINICAL CANCER RESEARCH, 2019, 25 (22) : 6598 - 6605
[7] Characterization of the enhanced potency of PI3K inhibitor taselisib (GDC-0032) in PI3K mutant cell lines and models
Edgar, Kyle A.
Nannini, Michelle
Hong, Rebecca
Eigenbrot, Charlie
Schmidt, Stephen
Young, Amy
Sampath, Deepak
Wallin, Jeffrey J.
Friedman, Lori S.
[J]. CANCER RESEARCH, 2015, 75
[8] ABSORPTION, METABOLISM, AND EXCRETION OF TASELISIB (GDC-0032), A PI3K INHIBITOR, IN RATS, DOGS, AND HUMANS
Ma, Shuguang
Salphati, Laurent
Srikumar, Srikumar
Takahashi, Ryan
Ding, Xiao
Pang, Jodie
Wang, Bing
Remarchuk, Travis
Hsu, Jerry
Hop, Cornelis
Ware, Joseph A.
Khojasteh, S. Cyrus
[J]. DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S74 - S75
[9] Absorption, Metabolism, and Excretion of Taselisib (GDC-0032) , a Potent fl-Sparing PI3K Inhibitor in Rats, Dogs, and Humans
Ma, Shuguang
Cho, Sungjoon
Sahasranaman, Srikumar
Zhao, Weiping
Pang, Jodie
Ding, Xiao
Dean, Brian
Wang, Bin
Hsu, Jerry Y.
Ware, Joseph
Salphati, Laurent
[J]. DRUG METABOLISM AND DISPOSITION, 2023, 51 (04) : 436 - 450
[10] A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors
Jhaveri, Komal
Juric, Dejan
Saura, Cristina
Cervantes, Andres
Melnyk, Anton
Patel, Manish R.
Oliveira, Mafalda
Gambardella, Valentina
Ribrag, Vincent
Ma, Cynthia X.
Aljumaily, Raid
Bedard, Philippe L.
Sachdev, Jasgit C.
Bond, John
Jones, Surai
Wilson, Timothy R.
Wei, Michael C.
Baselga, Jose
[J]. CANCER RESEARCH, 2018, 78 (13)

← 1 2 3 4 5 →